Innovation in the pharmaceutical and medical technologies industries of Poland by Wisła, Rafał & Sierotowicz, Tomasz
Innovation in the pharmaceutical 
and medical technologies industries 
of Poland
Rafał Wisła
Tomasz Sierotowicz
Jagiellonian University in Kraków
September
 2018
Economic Research
Working Paper No. 45
Abstract
This paper analyzes the recent economic and innovation trends of the health industries in Poland. 
The health industries have observed remarkable growth since entering into the EU. While the 
pharmaceutical industry faces some economic slowdown since 2011, the medtech industry shows 
substantial dynamism for its small size. The Polish health industry has still much to do to improve 
its innovation status. However, the observed trend of the innovation dynamics is cause for optimism. 
Polish firms in the health industries are increasingly innovating and extracting economic results from 
these innovations. 
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Introduction
For the last decade, healthcare expenditures in Po-
land have followed the pace of the economy (Euro-
stat, 2018). In 2006, the total healthcare expenditures 
amounted to 65.7 billion zlotys, representing 6.2 per-
cent of the gross domestic product (GDP). By 2015, the 
total healthcare expenditures reached 116.2 billion 
zlotys, or 6.3 percent of the GDP. This share is among 
the lowest in Europe, including those of most of the 
other Central and Eastern European (CEE) countries. 
The public and private split of these expenditures – 
around 70 and 30 percent, respectively – have also 
remained stable during the decade. 
Furthermore, changes in the age structure of the Po-
lish population bring serious social consequences 
and even more economic pressure to the healthcare 
system. They entail ever-increasing expenditures on 
ensuring people’s adequate quality of life and fitness 
at work. Together with the prevention and treatment 
of lifestyle diseases, such expenditures are of strate-
gic importance. New cures for untreated diseases or 
more cost-effective treatments can provide solutions 
to this challenge. As such, health-related innovations 
are increasingly becoming key areas of financial and 
institutional support provided by the public sector to 
the private one.
The objective of this paper is to present the recent eco-
nomic and innovation trends for the Polish health-re-
lated industries. For that purpose, this paper presents 
the results of a descriptive analysis of the economic and 
innovative activities of firms in the pharmaceutical and 
medical technologies (medtech) manufacturing indu-
stries.
In Poland, the pharmaceutical industry is composed 
mainly of firms manufacturing pharmaceutical pre-
parations. A limited number of companies supply 
the majority of the national production, which was 
mostly of generic medicines. This industry showed 
considerable growth after Poland’s entry to the Eu-
ropean Union (EU), but since 2010, it has stagnated in 
most economic indicators. In 2014, Poland continues 
to import more pharmaceuticals than it sells abroad. 
The medtech industry in Poland contains mostly small 
and medium-sized firms. Their technological and ma-
nufacturing potential is diversified, although mostly in 
the lower technological segments of manufacturing 
medical and dental instruments and supplies. 
The Polish health industry has still much to do to im-
prove its innovation status. The innovation rates are 
one of the lowest in the EU area. However, firms in 
the health industries are increasingly innovating and 
extracting economics results from these innovations. 
Firms develop new products, services, and new pro-
duction processes. These have allowed the industry 
to broaden the assortment of products, enter new 
markets, improve the quality of products, replace ob-
solete products and processes, and improve produc-
tion flexibility.
The paper is organized as follows: section 1 descri-
bes the methodological definitions and data sources 
employed; section 2 describes the economic context 
of the health sector; and section 3 explores the in-
novative behavior of these industries. A final section 
concludes by summarizing the main findings.
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In order to perform a descriptive analysis of the eco-
nomic and innovative activities of the health-related 
industries, we need to define its scope and which data 
sources to make use for measuring it. 
The main data sources employed in section 2 to de-
scribe the economic activities of the health industries 
are: the Statistical Yearbook of Industry (Central Stati-
stical Office, 2007-2018), the Specialist Report for the 
Technological Area: Medical Technologies (MedicaSILE-
SIA, 2015 and 2016), and the Annual Enterprise Statistics 
(Eurostat, 2017a). Section 2 analyzes several econo-
mic indicators for the period from 2000 to 2015, al-
though the focus is on 2005 to 2014. 
For all these sources, we define health industries as 
the sum of the manufacturing firms producing phar-
maceutical products and medical technologies. By 
focusing only on manufacturing firms, this study ex-
plicitly excludes the services segments of the health-
-related industries.
The practical definition of pharmaceutical industries 
follows the Statistical Classification of Economic Acti-
vities in the European Community, Rev. 2 (NACE, Rev.2, 
2008) and includes the manufacture of basic phar-
maceutical products and pharmaceutical prepara-
tions.1 The practical definition of medical technologies 
(medtech) industry follows the same classification 
and includes the manufacture of medical and dental 
instruments and supplies as well as the manufacture 
of irradiation, electromedical and electrotherapeutic 
equipment.2 
The statistical data publicly available concerning 
the medtech industry in Poland are rather limited in 
comparison to those related to the pharmaceutical 
industry. The main reason is that the pharmaceutical 
industry is more uniformly defined and completely 
visible at the second level of the NACE (Rev.2, 2008) 
statistical classification. Typically, the medtech indu-
stry appears in the lower levels of economic activities 
classifications, which are often less accessible in sta-
tistical reports.
1  NACE, Rev.2 codes 21.10 and 21.20, respectively.
2  NACE, Rev.2 codes 32.50 and 26.60, respectively.
3  OECD (2005). Oslo Manual, Guidelines for collecting and interpreting innovation data, OECD: Paris.
4  See OECD (2005).
5  Research and development (R&D) includes basic research, applied research (of which industrial research) and experimental development.
Another challenge concerning the measurement of 
the medtech industry refers to the size of the firms. 
Eurostat data reports 5,475, 5,683 and 6,076 Polish 
firms manufacturing medical and dental instruments 
and supplies (NACE, Rev.2 codes 32.50) in the years 
2012, 2013, and 2014, respectively. These numbers are 
hugely inflated. A thorough analysis shows that this 
is the result of relying on the classification of busi-
ness activities in Poland (PKD 2007), which takes into 
consideration self-employed sole traders, such as 
manufacturers of simple orthopedic equipment. The-
se numbers do not tally with the number of medtech 
firms in Table 4 or the number of members of the Po-
lish Medical Devices Economic Chamber, which was 
about 90 manufacturers and distributors of medical 
technologies in Poland in 2018.
The main data sources employed in section 3 to de-
scribe the innovative activities of the health indu-
stries are the Community Innovation Survey (CIS) na-
tional and European data (Central Statistical Office, 
2017; Eurostat, 2017b). The CIS surveys are based on 
the Oslo Manual3 methodology jointly developed by 
Eurostat and the Organization for Economic Co-ope-
ration and Development (OECD) and have as primary 
objective the understanding of the innovation acti-
vities undertaken by industrial enterprises.4 
Both sources follow the Oslo Manual definition of in-
novation activities: “Innovation activities include all 
scientific, technological, organizational, financial and 
commercial steps which actually lead, or are inten-
ded to lead, to the implementation of innovations. 
Some of these activities may be innovative in their 
own right, while others are not novel but are neces-
sary to implementation. Innovation activities also inc-
lude internal research and development (R&D)5 and 
acquisition of external knowledge or capital goods”.
According to the Oslo Manual, there are four basic ty-
pes of innovations: innovations related to products, 
processes, organization and marketing. Given the 
characteristics of the health industries, we will focus 
mainly on the product and process innovations. These 
two types of innovations are referred to as technolo-
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gical innovations. Following the Oslo Manual, we will 
consider a product innovation as the new or signifi-
cantly improved products already launched onto the 
market, and a process innovation as the new process 
already being used in the firm’s operations. 
In Poland, the CIS surveys are part of the national sta-
tistics research program, Innovations in the Industry, 
which covered all enterprises employing 50 and more 
people as well as a representative sample of 25 per-
cent of businesses employing from 10 to 49 people. 
For this paper, we made use of the microdata col-
lected by the Central Statistical Office of Poland for 
four CIS cycles: 2006–2008, 2008–2010, 2010–2012 
and 2012–2014.
Using microdata allowed us to extend the previous 
industry scope by including those Polish entities sub-
mitting patent applications to the Polish Patent Office 
(PPO) for pharmaceutical or medical technologies in 
the years 2006-2014. In concrete terms, we included 
those firms filing patents with the following IPC sym-
bols: A61B-C, A61F-H, A61J-N, A61P, C07H21, C12Q1/68, 
C12N15/11, G01N33/50 (with dependencies), H05G, 
C12Q1/68, C07H21, and C12N15/11. 
The sample of health-related firms covered by the four 
CIS cycles is highly representative of the whole health 
industry. However, in view of the relatively small num-
ber of firms surveyed, the analysis of the main features 
of the innovation activities in Poland are presented join-
tly for the pharmaceutical and medtech industries. 
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Poland’s pharmaceutical industry has undergone nu-
merous profound changes in the past 25 years. The 
changes affected the ownership structure of the sec-
tor’s entities, the regulations applicable to commer-
cializing medicines, and the administration of the pu-
blic health system.
Four years before Poland’s entry into the EU, the market 
for pharmaceutical products had a stable rate of growth 
in both the pharmacy and hospital segments (Table 1).1 
In 2003, the market for pharmaceutical products tota-
led 13,086 million zlotys. This is a 30.6 percent increase 
from its value in 2000 in nominal terms and a 20.5 per-
cent increase if measured at 2000’s prices.
The same pattern is observed for both the pharma-
cy and hospital segments, which remained equally 
distributed along those years. The pharmacy segment 
is predominant, representing around 88 percent of the 
market value. Most of the products sold are pharma-
ceutical preparations (98.6 percent of total sales), 
while basic pharmaceutical products represent the 
remaining portion (1.4 percent). Sulfonamides and 
packed pharmaceutical herbs are the most important 
product groupings among all pharmaceutical pro-
ducts sold.
Table 1. Market for pharmaceutical products in Poland 
(in producer’s prices*, in million zlotys).
2000 2001 2002 2003
total 10,020 11,088 11,566 13,086
pharmacy market 8,853 9,745 10,135 11,557
hospital market 1,167 1,343 1,431 1,529
Notes: (*) Producer’s price is defined as the value of sold production per 
unit of product (excluding value added tax, rebates and deductions, 
and including excise tax if applicable).
Source: INFARMA (2004)
1  Poland’s official entry date to the EU is May 1, 2004. 
During the period after the entry to the EU, the phar-
maceutical sector has observed an overall increase 
in most economic indicators. However, most of the 
increase occurred prior to 2010, and some negative 
trends have been observed since then. 
Pharmaceutical output increased since entry, but la-
tely it has followed an erratic path. By 2014, the pro-
duction of pharmaceutical products constituted 1.1 
percent of the global output of the manufacturing 
sector in Poland. In constant prices, this output was 
32 percent higher than 2005, but 4.5 percent lower 
than 2010. The entry of new firms partially explains 
the overall output increase since 2005. The number 
of pharmaceutical firms was 62 percent higher than 
2005. By 2014, there were 343 firms manufacturing 
pharmaceuticals products, of which 58 percent were 
firms employing less than 10 people. 
The entry of smaller companies and the economic 
downturn correlates with lower employment rates in 
the pharmaceutical industry. Since 2010, the industry 
has reduced by 2,000 posts – an 8 percent decrease – 
to 21,900 employees by 2014. Still, the average mon-
thly gross wages increased 8.3 percent from 2010 to 
2014. These opposite trends are reflected in the indu-
stry’s relatively stable cost, which oscillated between 
89.3 and 89.9 from 2010 to 2014.
Since 2010, the productivity and profitability of the in-
dustry has decreased, as has investment. In 2014, the 
gross value added per employee was 6 percent lower 
than 2010, while the sold output per employee was 
1.4 percent lower. Both gross and net profit margins 
were at their lowest since 2005, registering 10 and 8.5 
percent, respectively. Investments have been decre-
asing since 2005. Investment outlays were 9.2 percent 
lower in 2010 and 12.3 percent in 2014 than the 511.6 
million zlotys reached in 2005. 
2.1 Consolidated pharmaceutical industry
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By 2014, most of the industry’s economic activity was 
concentrated in a few firms. The 35 largest pharma-
ceutical companies – less than a quarter of the indu-
stry – accounted for 92 percent of the value of sold 
production and 76 percent of the employment (see 
Table 2). These firms employ 15,800 people and com-
mercialize 11 billion zlotys a year. The concentration 
coefficient for the value of sold production was sta-
ble from 2005 to 2010 at around 0.66, but it rose to 
0.71 in 2014. As a result, 17 firms account for 80 percent 
of the value of sold production in 2014. 
Poland has negative trade balance of pharmaceuti-
cal products (Table 3). The trade with the EU explains 
most of the imbalance, while the trade surplus with 
other countries in the region is the main counter ba-
lancing force. However, this deficit was reduced by 15 
percent from 2010 to 2014. In 2010, the value of the 
negative trade balance was 12.2 billion zlotys, whi-
le in 2014 it was 10.5 billion zlotys. Pharmaceutical 
2  The coefficient of sold production concentration is calculated according to an interpolative formula, constructed based on the Lorenz curve. The 
coefficient assumes values between 0 and 1; the higher the concentration, the closer the value of this coefficient is to 1. The concentration is understood 
as the irregularities in the distribution of a given phenomenon according to class size (i.e. deviation of the actual distribution from the regular 
distribution). 
exports outpacing the imports during this period 
explain the reduction. Exports increased 72 percent 
in this period, compared to an import increase of only 
16 percent.2
Table 3. Pharmaceutical trade balance by groups of countries (current prices, in million zlotys).
Source: Central Statistical Office (2015).
Notes: (1) Includes the UE28 countries, Australia, Canada, Cyprus, Israel, Japan, New Zealand, South Africa, United States, and other 
European countries (excluding: Bosnia and Herzegovina, Macedonia, Serbia, Montenegro and CEE countries); 
(2) Includes Albania, Belarus, Moldova, Russia, and Ukraine;
(3) Includes all other countries not included before.
Sector 2010 2013
2014
total
developed countries(1)
CEE
countries(2)
developing
countries(3)Total of which EU
Exports 6,704.9 9,872.8 11,510.8 9,180.4 8,242.2 1,352.5 977.9
Imports 18,936.4 20,563.9 21,967.1 19,223.7 16,716.1 14.6 2,728.9
Trade 
balance -12,231.5 -10,691.1 -10,456.3 -10,043.3 -8,473.9 1,337.9 -1,751.0
Table 2. Basic economic indicators of the pharmaceutical industry (in 2014).
Source: Central Statistical Office (2015). Notes: (1) entities conducting activity during the year. Data include only firms employing more than 9 persons.
Indicator Total
(Entities by value of sold production (in million zlotys
> 2.00 2.01-5.00 5.01-10.00 10.01-20.00 20.01-40.00 < 40.00
Number of active firms (1) 144 26 30 19 18 16 35
Value of sold production  
(in million zlotys, in current prices) 12,121.5 26.3 98.9 136.7 241.1 470.7 11,147.8
Employment (in thousands) 20.7 0.5 0.6 0.7 1.1 2.0 15.8
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The EU is not only the main origin of the pharmaceu-
tical imports but also the main destination of Polish 
exports. In 2014, 71.6 percent of Polish pharmaceu-
tical exports went to the EU, while other developed 
economies only accounted for 8.2 percent. Indeed, 
the latter represented less than the exports to other 
CEE markets (11.7 percent) and the rest of the world 
(8.5 percent).
Generic medicines represent a considerable share of 
the Polish medicine market. These drugs constitute 
half of all pharmaceuticals included in drug reimbur-
sement registers. The national government spends 
about 30 percent of its drug reimbursement budget 
on such generic drugs. In 2014, medicines produced 
domestically – which are mostly generic and branded 
generic – represent more than half of the units and 
a third of their value sold in Poland (Figure 1). Never-
theless, these shares have been falling since 2005. In 
a decade, the market share dropped from 65 percent 
to 53 percent in terms of units and from 35 percent 
to 30 percent in terms of value. The difference in the 
units and price falls indicates that the average relati-
ve price of the domestically produced medicines and 
the imported ones have converged to some extent. 
The price per unit of domestically produced medicine 
went from 29 percent of imported medicine in 2005 
to 38 percent in 2014. By 2014, the average price for 
a generic medicine in Poland was three euros (INFAR-
MA, 2015).
Figure 1. Market share of medicines manufactured domestically (net producer prices).
Source: INFARMA (2015).
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UNITS VALUE
How does the Polish pharmaceutical industry 
compare with other CEE countries?
We now benchmark the previous economic findings 
for the Polish pharmaceutical industry with those of 
other CEE countries.
The increase in number of pharmaceutical firms is 
also present in most of CEE countries (see Figure 2). 
Bulgaria and the Czech Republic are the main excep-
tions to this pattern. All reporting CEE countries show 
a higher number of firms manufacturing pharma-
ceutical preparations than those manufacturing ba-
sic pharmaceutical products (Figure 3). However, the 
distribution between these is not equivalent. Poland 
(30 percent) has the highest proportion of firms ma-
nufacturing basic pharmaceutical products among 
CEE economies. Bulgaria and Estonia (both at 8 per-
cent) have the lowest.
Relative to the population, Latvia had the largest 
number of pharmaceutical firms manufacturing basic 
pharmaceutical products and pharmaceutical prepa-
rations among CEE economies in 2014 (Figure 4). In 
2012, Poland was ranked first in firms manufacturing 
basic pharmaceutical products, while penultimate 
for those manufacturing pharmaceutical prepara-
tions. By 2014, Poland was second for the basic phar-
maceutical segment, but managed to overtake Czech 
Republic, Bulgaria and Hungary in the pharmaceuti-
cal preparations segment. The latter is explained not 
only by the increase in the number of Polish firms in 
those two years, but also by the decrease in the num-
ber of firms in Czech Republic and Bulgaria. Overall, 
these trends suggest different specialization patterns 
arising in the region.
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Figure 3. Distribution of pharmaceutical firms, 2014, selected CEE countries.
Source: Eurostat (2017a).
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Figure 2. Recent evolution of the number of pharmaceutical firms, selected CEE countries (2012 = 100).
Source: Eurostat (2017a).
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Relative to the population, Latvia had the largest 
number of pharmaceutical firms manufacturing basic 
pharmaceutical products and pharmaceutical prepa-
rations among CEE economies in 2014 (Figure 4). In 
2012, Poland was ranked first in firms manufacturing 
basic pharmaceutical products, while penultimate 
for those manufacturing pharmaceutical prepara-
tions. By 2014, Poland was second for the basic phar-
maceutical segment, but managed to overtake Czech 
Republic, Bulgaria and Hungary in the pharmaceuti-
cal preparations segment. The latter is explained not 
only by the increase in the number of Polish firms in 
those two years, but also by the decrease in the num-
ber of firms in Czech Republic and Bulgaria. Overall, 
these trends suggest different specialization patterns 
arising in the region.
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Figure 4. Number of pharmaceutical firms per 1 million inhabitants, selected CEE countries.
(a) Basic pharmaceutical products   (b) Pharmaceutical preparations
Source: Eurostat (2017a).
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Figure 5. Number of employees in the pharmaceutical industry per 10,000 employed workers in the economy, selected 
CEE countries.
(a) Basic pharmaceutical products   (b) Pharmaceutical preparations
Source: Eurostat (2017a).
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Figure 6. Value added at factor cost (in million euros), Pharmaceutical industry, selected CEE countries.
(a) Basic pharmaceutical products   (b) Pharmaceutical preparations
Source: Eurostat (2017a).
Pharmaceutical firms employ a relatively low share of 
the workforce in all CEE countries. In 2014, the Polish 
pharmaceutical industry employed 21,900 workers, 
which was the highest in the region. This constitutes 
just 0.1 percent of the total workforce and 0.2 percent 
of all those working in firms employing more than 
nine people. Other CEE economies – such as Hungary, 
Croatia and Latvia – observe higher proportions, but 
still below 0.5 percent of the workforce. Similar to 
other countries in the region, 10 percent of the phar-
maceutical industry workforce is employed in the 
manufacturing of basic pharmaceutical products, 
while the other 90 percent works in the production of 
pharmaceutical preparations.
Average firm size is decreasing in terms of employ-
ment. Despite the clear upward trend from 2012 to 
2014 in the number of pharmaceutical firms in the re-
gion, the number of employees in the pharmaceuti-
cal industry remains relatively unchanged in relation 
to overall employment (Figure 5). This indicates that 
newly established pharmaceutical firms in CEE coun-
tries employ fewer workers on average, which repli-
cates the pattern observed for Poland.
The manufacture of pharmaceutical preparations 
dwarfs the value added by the manufacture of basic 
pharmaceutical products in all CEE countries (Figure 
6). Poland and Hungary had the largest pharmaceuti-
cal industries in terms of value added at factor cost 
in the region from 2012 to 2014. Despite having fewer 
firms than Poland, Hungary had the highest value ad-
ded at factor cost for firms manufacturing pharma-
ceutical preparations in 2014. This correlates with the 
observed high percentage of employees in this sector.
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Poland has high productivity in basic pharmaceutical 
products but lags in pharmaceutical preparations. In 
2014, the ratio of value added at factor cost to num-
ber of employees for the firms manufacturing basic 
pharmaceutical products in the region ranged from 
10,000 to 40,000 euros per employee (€/emp). The 
Czech Republic (40,000 €/emp) and Poland (35,000 
€/emp) led the region, followed by Romania (26,000 
€/emp) and Hungary (10,000 €/emp). Using the same 
ratio, Lithuania (89,000 €/emp) and Hungary (71,000 
€/emp) had the highest levels of productivity in the 
manufacture of pharmaceutical preparations in 2014. 
These were followed by Croatia (57,000 €/emp), Po-
land (48,000 €/emp), the Czech Republic (45,000 €/
emp) and Romania (34,000 €/emp). 
Hungary is the leader of pharmaceutical exports 
among the CEE economies (Figure 7). Poland, Slove-
nia and the Czech Republic follow it. All these coun-
tries report high export growth rates. However, Po-
land’s growth from 2010 to 2014 was higher than the 
other CEE countries, increasing at the average annual 
rate of approximately 27 percent (DELab UW, PZPPF, 
2015, p. 9). In 2004, Poland’s pharmaceutical exports 
were below those of Slovenia and the Czech Repu-
blic; by 2014, they were only below those of Hungary. 
Poland’s pharmaceutical exports are worth 2.7 billion 
euros, which constitutes 1 percent of the total exports 
of the EU 28 countries. Despite increasing exports, the 
persistent high import rate means that Poland is among 
the most import-dependent EU countries, along with 
Portugal and Spain. In the region, Hungary and Slovenia 
have the highest trade surpluses, which are around 1 bil-
lion euros (DELab UW, PZPPF, 2015, p. 9).
Figure 7. Pharmaceutical exports, selected CEE countries.
(a) in billion euros
(b) as a share of CEE exports
Source: DELab UW, PZPPF (2015)
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Figure 8. Average price of generic medicines (in euros), 2014.
Source: INFARMA(2015).
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The price of pharmaceuticals in Poland is among the 
lowest in Europe (Figure 8). The average price of a 
generic drug is 3.0 euros in Poland, second only to 
Bulgaria (2.6 euros). The average prices in CEE coun-
tries such as Slovenia (4.9 euros), the Czech Republic 
(4.0 euros) and Hungary (3.8 euros) are substantially 
higher. However, the CEE economies are far below the 
highest prices in Europe, which are observed in Swi-
tzerland (13.4 euros), Germany (10.1 euros) and Finland 
(9.4 euros).
The share of public expenditures in medicine costs 
incurred by patients in Poland is among the lowest in 
the OECD countries. It constitutes just 32 percent of 
the purchase cost, while the average for the 26 OECD 
countries is 57 percent. Poland’s share is also lower 
than other CEE countries, such as Hungary (43 per-
cent), Slovenia (48 percent), Estonia (54 percent), and 
Czech Republic (62 percent). Among other things, this 
is the result of the limited therapeutic groups covered 
by the public system in Poland. 
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The medical technologies (medtech) industry is devel-
oping particularly quickly in highly industrialized coun-
tries with competitive economies and high values of 
GDP per capita. The use of state-of-the-art technolo-
gies characterizes the medtech industry. This section 
explores the recent evolution of the Polish medtech in-
dustry.
The Polish medtech industry includes approximately 90 
large and small business entities manufacturing medi-
cal devices and the consumables indispensable for their 
operation, such as electrodes, catheters, infusion sets, 
etc. Typically, these are small and medium-sized firms. 
In 2014, the medtech annual value of production output 
amounted to about five million zlotys. The technologi-
cal and manufacturing potential is diversified, but it is 
not too high (MedicaSILESIA, 2015). The same applies 
to the competitiveness of the Polish medtech industry. 
There are few medtech companies with more than 
nine employees (Table 4). Nevertheless, these medtech 
firms have been growing at a steady pace. From 2011 to 
2014, the medtech firms increased in number (15 per-
cent), employment (27 percent), salaries (13 percent), 
capitalization (76 percent) and output (65 percent). The 
industry’s capitalization and output have observed rapid 
growth, which contrasts with the declining values ob-
served for the pharmaceutical industry in section 2.1. 
By 2014, there were 46 medtech firms employing 11,000 
workers, having 1.6 billion zlotys in fixed assets and pro-
ducing 3.1 billion zlotys. Including the self-employed and 
micro companies, the value of medtech products sold in 
Poland exceeded 6.5 billion zlotys in 2013, a significant 
increase on the 3.9 billion zlotys achieved in 2010.
Table 4. Basic economic indicators of the medtech indu-
stry.
Year
Number of 
active firms 
(1)
Employment 
(in thousands)
Average 
monthly 
gross wage 
(in zlotys)
Gross value 
of fixed 
assets
(in million 
zlotys)
2011 40 8.6 3429.8 886.9
2012 42 9.3 3634.6 993.7
2013 45 10.6 3741.2 1398.3
2014 46 10.9 3889.9 1563.8
Source: Central Statistical Office (2012, 2013, 2014 and 2015). Includes 
only firms of the manufacture of medical and dental instruments and 
supplies sector employing more than nine persons. Gross value of fixed 
assets expressed in current bookkeeping prices.
In terms of market size, the main segment of the 
medtech industry is the manufacturing of medical 
and dental instruments and supplies. Firms manufac-
turing medical equipment accounted for less than 4 
percent of the total value of the sold production in 
2014 (Table 5). 
Table 5. Value of sold production of the medtech industry 
(producer prices, million zlotys).
Sector 2011 2012 2013 2014
Manufacture of 
medical and den-
tal instruments 
and supplies
1783.5 2323.3 2546.7 2957.1
Manufacture of 
irradiation, elec-
tromedical and 
electrotherapeu-
tic equipment
76.6 88.8 94.9 117.5
Total medtech 1860.1 2412.1 2641.6 3074.6
Source: Central Statistical Office (2012, 2013, 2014 and 2015). Includes 
only firms employing more than nine persons.
One of the drivers of higher medtech sales is exports, 
which reached 2.5 billion zlotys in 2014. Poland’s 
medtech exports increased rapidly, more than tripling 
over the past few years (MedicaSILESIA, 2015). The EU 
is the main destination of Poland medtech exports, 
with Germany, Denmark and France accounting for 60 
percent of all exports. The main exported products 
are hospital furniture, precision surgery tools, medi-
cal consumables and implants. This can also be ob-
served in the increasing presence of Polish medtech 
firms at the Dusseldorf’s Medica Trade Fair. Many of 
these firms have benefited from public support for 
their participation.
The funds available under the European Cohesion 
Policy and Regional Operational Program – of which 
Poland is a major beneficiary – constitute another 
explanation for the growing demand for medical 
tools, devices, equipment, software and consumab-
les.
2.2 The new and vibrant medical technologies industry
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How does the Polish medical technologies 
industry compare with other CEE countries?
This section compares the medtech industries in CEE 
countries. The main criteria for comparison are: the 
number of enterprises, the number of persons em-
ployed in the sector, and value added at factor cost.
Most CEE countries have seen an increase in medtech 
firms (Figure 9). Croatia, Hungary and Slovakia are the 
main exceptions to this pattern. Poland increased 11 
percent from 2012 to 2014, only outpaced by Latvia (18 
percent), Romania (17 percent) and Lithuania (14 per-
cent). All reporting CEE countries show an overwhel-
ming increase in the number of firms manufacturing 
medical and dental instruments and supplies (Figu-
re 10). In 2014, Hungary (5.8 percent) had the largest 
proportion of firms manufacturing irradiation, elec-
tromedical and electrotherapeutic equipment, while 
Poland (1.5 percent) had the lowest among CEE eco-
nomies.
Figure 9. Recent evolution of the number of medtech firms, selected CEE countries (2012 = 100).
Source: Eurostat (2017a).
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Figure 10. Distribution of medtech firms, 2014, selected CEE countries. 
Source: Eurostat (2017a).
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Relative to the population, the Czech Republic had 
the largest number of medtech firms manufacturing 
medical and dental instruments and supplies among 
the CEE economies (Figure 11). In 2014, Poland was 
ranked fourth, and very close to Slovenia in third. 
Hungary ranks first in firms manufacturing irradiation, 
electromedical and electrotherapeutic equipment 
per million people. 
Figure 11. Number of medtech firms per 1 million inhabitants, selected CEE countries.   
(a) Medical instruments and supplies         (b) Medical equipment
Source: Eurostat (2017a).
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Figure 12. Number of employees in the medtech industry per 10,000 employed workers in the economy, selected CEE 
countries.   
(a) Medical instruments and supplies         (b) Medical equipment
Source: Eurostat (2017a).
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Despite the growing number of firms, employment 
in the medtech industry has remained stable in most 
CEE countries. With the notable exceptions of Poland, 
Romania and Croatia, employment in the medtech in-
dustry remained stable relative to the rest of the eco-
nomy (Figure 12). Poland and Romania observed the 
largest increase, and Croatia the most noticeable de-
crease. In Poland, employment in medtech represen-
ted 0.15 percent of the total workforce in 2014, far be-
low the shares in the Czech Republic (0.32 percent), 
Hungary (0.31 percent), and Slovenia (0.2 percent).
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Figure 13. Value added at factor cost (in million euros), medtech industry, selected CEE countries.   
(a) Medical instruments and supplies         (b) Medical equipment
Source: Eurostat (2017a).
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In 2014, Poland had the largest medtech industry in 
terms of value added at factor cost among the CEE 
countries (Figure 13). Poland’s value added totaled 
403.6 million euros, which is followed by the Czech 
Republic (300.9 million euros) and Hungary (275.3 
million euros). 
However, Poland lags in productivity among the CEE 
countries. The average productivity for firms ma-
nufacturing medical and dental instruments and 
supplies ranged from 25,000 euros per employee (€/
emp) in Slovenia to 16,000 €/emp in Croatia. Within 
this range, Slovenia was followed by Slovakia (22,000 
€/emp), Hungary (21,000 €/emp), the Czech Republic 
(19,000 €/emp), Latvia (18,000 €/emp) and Poland 
(17,000 €/emp). In the case of firms manufacturing 
irradiation, electromedical and electrotherapeutic 
equipment, the range of productivity values was even 
narrower, ranging approximately from 21,000 €/emp 
in the Czech Republic, Croatia, Hungary and Poland to 
18,000 €/emp in Estonia.
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In order to achieve new or significantly improved 
products or processes, firms can invest in innova-
tion through different innovation activities. Firms can 
invest in internal R&D activities or acquire it from out-
side. Firms can invest in innovation by acquiring tech-
nology through licensing in external knowledge, pur-
chasing software or training personnel, and also by 
purchasing capital goods – i.e. machinery and equip-
ment – with embedded technology. Firms can also 
potentiate innovation by investing in marketing new 
or significantly improved products and processes.
Health-related industries are among the top innova-
tion expending sectors. In Poland, expenditures on 
innovation activities in the health industries have in-
creased by 51 percent between 2008 and 2014. The 
total innovation expenditure was 581 million zlotys in 
2008, 562 million zlotys in 2010, 564 million zlotys in 
2012, and 876 million zlotys in 2014.
In 2014, the share of firms investing in innovation ac-
tivities in the health industries was much higher than 
the share observed for the whole economy. The sha-
re for the pharmaceutical industries was 51 percent. 
Similarly, the share for medtech technologies was 
42.4 percent for the devices segment and 28.8 per-
cent for medical instruments. Nevertheless, all these 
shares were among the lowest values across all EU 
countries. 
R&D expenditures represent the largest share of in-
novation expenditures (Figure 14). From 2008 to 
2014, the R&D expenditures share in total innovation 
expenditures was 46 percent, of which 37 percent 
was performed in-house and 9 percent outsourced. 
The pharmaceutical industry accounts for a large 
1  Comparison of figures in Table 6 and Figure 14 is limited as their sampling coverage differ.
2  Gross domestic expenditure on R&D (GERD) includes expenditure on research and development by business enterprises, higher education institu-
tions, as well as government and private non-profit organizations.
3  These exclude investments in R&D related assets.
portion of these R&D expenditures (Table 6).1 The R&D 
expenditures of the pharmaceutical industries have 
increased by an average annual rate of 11.4 percent 
since 2011. In 2014, these expenditures amounted to 
268.9 million zlotys, which constituted 1.7 percent of 
Poland’s gross expenditure on R&D (GERD)2. In com-
parison to 2011, these expenditures grew by 74.6 mil-
lion zlotys, but their share in Poland’s GERD remains 
unchanged.
The health industries invested 143 million zlotys in 
capital goods with embedded technology in 2014 (Fi-
gure 14).3 Similarly, the health industries invested 228 
million zlotys in marketing related to the launch of 
new or significantly improved products in 2014. The-
se two types of investments have observed an erratic 
path from 2008 to 2014. Capital and marketing inno-
vation investments accounted for 20.4 percent and 
19.2 percent, respectively, of total innovation expen-
ditures from 2008 to 2014. The remaining innovation 
activities – namely, training, purchasing software and 
purchasing external technology – constituted around 
13 percent of the total expenditures. 
This section aims to highlight the innovation dyna-
mics of the Polish health industries. Innovations in the 
health sector are related mainly to new or improved 
medical technologies, therapeutic methods, and me-
dical products. However, innovation activities occur 
also wherever the effective management of the he-
alth sector and medical institutions is combined with 
the efficient organization of service provision systems 
oriented towards achieving high levels of both custo-
mer satisfaction and cost performance. 
This section focuses on investment in innovation ac-
tivities and the innovation outcomes. It also addres-
ses how innovation is created, acquired or co-created 
through cooperation. A final subsection explores the 
main barriers to innovation in Poland. 
3.1 Investing in innovation
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Figure 14. Expenditures in innovation activities (current prices, in million zlotys).
 
Source: Central Statistical Office (2017). Notes: some activities have some missing data points.
Table 6. R&D expenditures of the pharmaceutical industry (current prices, million zlotys).
Year Total R&D expenditures
R&D expenditures funded by
Expenditu-
res on R&D 
capital
Expenditures on research 
equipment
Gross
value
Degree of 
consumption 
(in %)
Public sector Own funds Other
2011 194.3 12.3 159.3 22.7 13.4 114.2 74.3
2012 259.0 5.4 242.1 11.5 25.0 100.5 76.5
2013 242.5 16.5 217.9 8.1 19.3 154.5 75.1
2014 268.9 22.5 231.2 15.2 48.7 208.4 79.1
Source: Central Statistical Office (2012, 2013, 2014 and 2015).
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Figure 15. Firms benefiting from public support by program, 2012-2014.
 
Source: Central Statistical Office (2017).
Firms in the health industry could count on various 
forms of public support. The most important institu-
tion providing support for innovation activities was 
the European Cohesion Policy and Regional Opera-
tional Program from the European Commission. This 
program pursues policy objectives at the regional 
level providing support for innovation activities con-
ducted by firms in the health sector. The main areas of 
support were investment on fixed assets (50 percent), 
R&D activities (40 percent) and exports (28 percent). 
Support at the national level was also more frequ-
ently used for investment in fixed assets (17 percent) 
and R&D activities (21 percent). Support for the co-
operation between academia and business was the 
only program where national support (7 percent) was 
higher than European support (4 percent). Local sup-
port programs were less frequently used. The most 
used local support was for investment on fixed assets 
(4 percent).
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In order to improve its productivity and profitability, a 
firm can introduce many changes in its operating me-
thods, the manner of utilizing its means of production 
or the types of manufactured products. These tech-
nological innovations can be new for the entire world, 
a region or just the country where the firm operates.
In general, innovation outcomes are relatively less 
frequent in Poland than in other EU countries. In 2014, 
the share of firms innovating their product or services 
 
 
 
 
was 16 percent in Poland, far below the highest share 
in the EU of 55 percent (Germany). Poland’s share is 
similar to other CEE countries, such as Estonia, Bul-
garia, Hungary, Latvia and Romania, which also rank 
among the lowest in EU. In 2014, the share of innova-
tive firms in CEE economies ranged from 12.8 percent 
in Romania to 26.5 percent in Estonia. Poland’s share 
was 21 percent in the same year, which was 7 percen-
tage points down from 2008.
3.2 Innovation outcomes
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Small companies in Poland also struggle to achieve 
the same innovation rates as other EU economies. The 
share of innovative small firms in Poland was 11 per-
cent, while the average for other EU countries was 28 
percent.4
The health industry performs better than the national 
average, but it is still far below EU levels. In the pe-
riod from 2006 to 2014, 35 percent of the firms in the 
health industry had a products innovation, 7.5 percent 
had a service innovation and close to 20 percent had 
process innovation. However, the historical analysis of 
the innovation surveys suggests an unfavorable trend. 
The share of product innovating firms fell from 41.4 
percent in 2006 to 34.5 percent in 2014; and the share 
of process innovating firms dropped from 27.8 percent 
in 2006 to 14.7 percent in 2014. There is only a mode-
rate increase in the share of service innovating firms 
from 8.3 percent in 2006 to 9.0 percent in 2014. 
Most of the product innovations in the health industry 
were only new to the firm (Figure 16). Only a quarter of 
firms claims that their product innovation was at least 
new in Poland. Process innovating firms have a similar 
pattern. In the period from 2012 to 2014, 88 percent of 
4 Small firms are defined as having 10 to 49 employees.
5  The increase is particularly noticeable if compared to 2012’s level, but it should be noted that a slowdown in the economic growth characterized 
the period between 2010 and 2012.
process innovating firms did not consider their inno-
vations novel in their main market. In the same period, 
there is a noticeable increase in the share of firms cla-
iming to have introduced product innovations for the 
first time in Europe (8.3 percent), of which more than 
a quarter claim to be new to the world.
These innovations have increasingly contributed to 
the revenue of the health industry firms since 2008 
(Table 7), with 2012 as the only exception. In 2014, the 
share of revenues relating to sales of new or signifi-
cantly improved products summed 11.1 percent. This 
was 2.3 percentage points more than the average 
share in Poland and a remarkable 58 percent increase 
from the 2008 figure.5 Within the innovative sales, the 
larger share relates to innovations that are new to the 
firm but not the market. In 2014, the share of inno-
vative products only new to the firm was 63 percent. 
However, the fast-paced growth of the share of inno-
vative sales is certainly related to the increase of re-
venues from innovations for the market. The share of 
revenues from these innovations increase 116 percent 
from 2008, while those only new to the firm increased 
only 30 percent. 
Figure 16. Product innovation by novelty type.
 
Source: Central Statistical Office (2017).
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How do firms in the health industry protect their in-
novations? 
The majority of firms in the health industry indicated 
the complexity of their products (56 percent), secrecy 
(52 percent) and lead-time advantage (45 percent) as 
effective mechanisms to maintain or improve com-
petitiveness in their markets (Figure 17). About one 
third of companies indicated trademarks (32 percent) 
and industrial designs (29 percent) as an important 
mechanism, which is in line with an industry where 
generic and branded generics dominate.
Only 23 percent of firms considered patents an effec-
tive mechanism to maintain or improve competitive-
6 Only two companies have filed more than 30 patent applications in the period analyzed.
ness in their markets. However, this number is not as 
low as it may appear, as only 35 percent of firms cla-
imed to achieve a product innovation. Moreover, most 
of these were not eligible for patent protection as 78 
percent of these were not new even in Poland. 
In 2014, health-related patent applications accounted 
for 9 percent of all domestic applications. This share 
is much higher than the equivalent share of health-
-related R&D expenditures. Nevertheless, academic 
institutions were responsible for a large portion of 
these patent applications, while firms hold relatively 
small patent portfolios (Gołacki et al, 2018).6 
Table 7. Innovation related revenues of the health industry.
Share of revenues related new or significantly 
improved products 2008 2010 2012 2014
All innovations 7.3 7.8 3.9 11.1
New to the market in which the enterprise operates 1.9 2.3 1.6 4.1
Only new to the firm 5.4 5.5 2.3 7.0
Source: Central Statistical Office (2017).
Figure 17. Appropriation of innovation outcomes, 2012-2014.
 
Source: Central Statistical Office (2017).
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Creating and acquiring knowledge in a firm is an inte-
gral part of the innovation process. Most innovating 
firms in the Polish health industries source informa-
tion internally (Figure 18). Among innovative firms: 82 
percent consider their own R&D facilities, manage-
ment, marketing departments or sales departments 
as a highly or very highly relevant source of infor-
mation; 59 percent consider it very high; 32 percent 
consider the same for other business within the same 
group, including the headquarters. 
Roughly half of the innovating firms considered the 
market and value chain as a highly or very highly re-
levant source for innovation: 50 percent indicated 
suppliers of machinery, technical equipment, mate-
rials, components and software; 44% pointed to cu-
stomers; and 45% indicated esteemed competitors 
and other businesses in the same sector. 
The health industry also relied extensively on some 
academic and specialized sources: 62 percent of in-
novating firms considered conferences, fairs, and 
exhibitions as highly relevant sources; and 57 percent 
indicated the same about scientific, technical and 
commercial periodicals and publications. Scientific, 
technical and professional associations gathered less 
appreciation (31 percent). 
However, academic institutions were among the least 
popular sources: 21 percent pointed to higher edu-
cation institutions, 19 percent to research institutes, 
12 percent to the Polish Academy of Sciences, and 
10 percent to foreign public research institutions. All 
these academic institutions were below the 23 per-
cent obtained by consulting companies, commercial 
laboratories and private R&D.
Figure 18. Sources of information for innovation, 2006-2014.
Source: Central Statistical Office (2017). Notes: Group contains headquarters and other businesses constituting joint property; PRO = public research 
organization; PAN = Polish Academy of Sciences.
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As with the whole country, the firms in the health in-
dustry acquire more technology than they transfer 
out (Figure 19). In the last CIS survey, more firms in-
dicated purchasing production processes automation 
systems (12 percent), but those acquiring consulting 
services (9.6 percent), licenses (9.5 percent) and R&D 
(9.4 percent) were also significant. In the same period, 
only 2.1 percent of firms indicated selling R&D, 1.3 per-
cent granted licenses, 0.8 precent provided consulting 
services, and 0.3 percent sold production processes 
automation systems.
Most surveyed firms purchased or sold new techno-
logies in Poland. In the case of foreign transactions, 
most of these were with partners in the EU area. Po-
lish firms rarely source the remaining European coun-
tries or the United States (US) for new technological 
solutions. Polish technologies are also sold mainly in 
the domestic and EU markets. In all CIS surveys, firms 
in the health industry indicated granting 96 licenses in 
total, all of them to European countries.
Cooperating with other firms and stakeholders con-
stitutes an important element of innovative business 
practices. Cooperation in the area of innovation acti-
vities entails the active participation in joint projects 
with other firms and non-commercial institutions 
seeking to share experience and knowledge.
The Polish government provides financial and institu-
tional support to increase collaboration in the health 
industries. One of the main initiatives is the STRATEG-
7 The National Research Program. Guidelines for the country’s policies concerning science, technology and innovativeness – Enclosure to resolution 
no. 164/2011 of the Council of Ministers of 16 August 2011 
MED framework managed by the National Centre for 
Research and Development (NCBR), which focuses 
on “prevention practices and treatment of civilization 
diseases”.7 This initiative considers civilization dise-
ases to be short-term hazards to the population and 
a result of aging population, the exposure to adverse 
environmental conditions and negative changes in li-
festyles (NCBR, 2012). STRATEGMED’s main objective 
is to stimulate collaboration between research en-
tities and entrepreneurs to improve innovation and 
Figure 19. Purchasing and selling new technologies.
(a) Purchase       (b) Sale 
Source: Central Statistical Office (2017).
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competitiveness in areas such as biotechnology and 
biomedical engineering. Annex 2 lists the research, 
development and implementation projects which are 
being carried out by scientific and industrial consortia 
in Poland. 
Cooperation is crucial for innovation activities in the 
health sector. In the period from 2006 to 2014, an 
average of 53 percent of innovating firms in the he-
alth industries claimed to have cooperated for the 
purpose of innovation. This was about 25 percenta-
ge points higher than Poland’s industry average. 45 
percent of cooperating firms did it with one to three 
partners, while 35 percent did it in larger consortia (4 
to 10 partners).
The share of health industry firms considering co-
operation with academic institutions as fruitful for 
innovation has increased greatly (Figure 20a). The-
re is also a noticeable change in the structure of the 
cooperation network between the public academic 
sector and private enterprises (Figure 20b). In the pe-
riod from 2012 to 2014, cooperating firms collabora-
ted more with universities and public research orga-
nizations (PROs), which contrasts with the decreasing 
cooperation with the units of the Polish Academy of 
Sciences. The increase in collaborations with univer-
sities and research institutes overcomes the higher le-
vel of collaboration observed for consulting and pri-
vate R&D firms, which also observed a large increase 
in the same period. 
Figure 20. Distribution of collaborating firms by most beneficial partner type.
(a) Grouped types     (b) Detailed types
Source: Central Statistical Office (2017). Notes: Group contains headquarters and other businesses constituting joint property; PRO = public research 
organization; PAN = Polish Academy of Sciences.
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With the exception of the last period, about a quar-
ter of cooperating health industry firms considered 
customers to be their most beneficial partner (Figure 
20a). This trend hides a steep decreasing trend with 
regard to the relevance of customers of the private 
sector (Figure 20b). The positive trend of the custo-
mers from the public sector compensated this fall 
until the period from 2010 to 2012. The falloff in the 
relevance of collaborations with suppliers followed a 
similar path to customers of the private sector. 
Contrary to attitudes to suppliers and customers, 
firms steadily consider cooperation within the busi-
ness group to be beneficial to achieving innovation. 
However, collaborations within the business group 
remain increasingly constrained within Poland or the 
EU (Figure 21). Cooperation with partners of the same 
group from outside Europe constitutes a clear mino-
rity.
Figure 21. Share of firms cooperating within business group by location of partner.
Source: Central Statistical Office (2017).
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The existence of innovation barriers partly explains 
the relatively low levels of innovation activities in 
Poland. Their sources are elements of the institutio-
nal environment and innovativeness support mecha-
nisms, which are still very different from those follo-
wed in highly innovative countries. 
The National Bank of Poland (2015) identified several 
limitations of the Polish national innovation system. 
There was a low level of social capital and public 
R&D, and a low mobility of the capital and human 
resources. There was both low quantity and quality 
of scientific publications. Internationally, there was a 
low number of grants received from the European Re-
search Council and limited participation in internatio-
nal research cooperation. There was a considerable 
distance to the technological frontier, which makes 
importing and imitating technologies cheaper than 
developing them independently. In addition, there 
was an unstable law regime and ineffective enforce-
ment of contractual obligations as a result.
Similarly, the NCBR (2012) also identified a series of 
major failure risks as barriers to succeeding in colla-
borative projects. There is a risk of cooperation based 
only on businesses and scientific partners seeking the 
3.4 Barriers to innovation development
short-term advantages of participation in such a pro-
ject. The divergent cooperation objectives of scienti-
fic institutions and business enterprises also poses a 
risk. There is a risk of limited business competences 
related to the economic implementation of project 
results by scientific partners. Finally, there is a risk of 
insufficient legal services provided to scientific insti-
tutions with respect to patent protection of research 
outputs.
The firms in the health industries also indicated the-
ir perceived barriers to innovation in the CIS surveys 
(Figure 22). 53 percent of firms cited innovation costs 
as an important barriers to innovation. Similarly, firms 
identified their own lack of financial resources (48 
percent) and the difficulties to find external ones (41 
percent) as major barriers. Market conditions are also 
frequently suggested barriers: firms believe that an 
uncertain demand for innovation (44 percent) and the 
Figure 22. Barriers to innovations and their importance.
Source: Central Statistical Office (2017).
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market dominant position of another firm (42 percent) 
prevents them from taking risks. Lack of highly quali-
fied personnel, information on existing technologies, 
demand, or partners for cooperation were indicated 
by approximately one third of the firms.
When asked to identify the main reasons for the poor 
development of innovations, 74 percent of health in-
dustry firms indicated a lack of convincing arguments 
for implementing innovations. The other firms did con-
sider implementing innovations but concluded that the 
identified barriers would prevent their success.
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The analysis of selected economic and innovation 
aspects of the Polish health industries – namely, the 
pharmaceutical and the medtech industries – allow 
us to derive some general conclusions.
Generic medicines represent a considerable share of 
the Polish market of medicines and the price of phar-
maceuticals is among the lowest in Europe. The share 
of public expenditures in the medicine costs incur-
red by patients in Poland is one of the lowest among 
the OECD countries. The Polish pharmaceutical indu-
stry observed a remarkable growth after joining the 
EU but has faced a severe slump since 2011. Similar 
to most CEE countries, Poland has observed an in-
crease in number of pharmaceutical firms. The entry 
of smaller companies and the economic downturn 
correlates to employment reduction, which is also 
observed in other CEE countries. Still, Poland has the 
larger pharmaceutical workforce in the region. 
The manufacture of pharmaceutical preparations is 
the largest segment of the pharmaceutical industry 
for all CEE economies. Poland has the largest basic 
pharmaceutical products segment within the region 
and has improved its position in the pharmaceutical 
preparations segment. Since 2010, the productivity 
and profitability of the Polish pharmaceutical indu-
stry decreased, as has investment. Poland still has 
the highest productivity in the basic pharmaceutical 
products segment among CEE countries, but lags in 
the pharmaceutical preparations segment. 
The medtech industry has grown steadily since 2011 
but it is still a small industry in terms of firms and 
output. The Polish medtech industry includes ap-
proximately 100 large and small business entities 
manufacturing medical technologies. However, the-
se have been growing at a steady pace, which is also 
the case for most of the CEE region. Poland has also 
observed increasing medtech sales, which is par-
tially due to exports and public support through the 
European Cohesion Policy. Poland also observed the 
largest increase in medtech employment, which re-
mained stable in most CEE countries. Poland has the 
largest medtech industry among the CEE countries, 
but it lags in productivity. In all CEE economies, the 
manufacturing of medical and dental instruments 
and supplies is by far the main medtech segment, but 
Poland had the lowest proportion of firms manufac-
turing medical equipment.
The Polish health industry has still much to do to im-
prove its innovation status. However, the observed 
trend of the innovation dynamics is cause for optimi-
sm. Polish firms in the health industries are increasin-
gly innovating and extracting economic results from 
these innovations. 
Health-related industries are among the top innova-
tion expending sectors in Poland. R&D expenditures 
represent the largest share of innovation expenditu-
res, followed by investments in capital goods with 
embedded technology and in marketing related to the 
launch of new or significantly improved products. The 
Polish health industry has made use of various forms 
of public support to finance innovation. The most 
used source of funding was the European Commis-
sion. Support for the cooperation between academia 
and business was the only program where the natio-
nal support was greater than European support. The 
local support programs were less frequently used to 
a significant degree.
The Polish health industry has innovated more than 
the national average, but it is still far from EU levels. 
Most of the product and process innovations were 
new only to the firm and only a quarter were new in 
Poland. However, these innovations have increasin-
gly contributed to the revenue of the health industry. 
Within the innovative sales, the larger share relates 
to innovations that are new to the firm but not the 
market. The health industry relies on complexity of 
their products, secrecy and lead-time advantage to 
maintain or improve competitiveness in their markets. 
Being a market dominated by generic and branded 
generics, less than a third relied on trademarks and 
industrial designs to maintain competitiveness. About 
a quarter relied on patents, which is in line with few 
novel product and process innovations being introdu-
ced to the Polish market. 
Most Polish innovating firms in the health industry re-
lied on information sourced internally and almost half 
relied on customers or suppliers. The health industry 
also relied extensively in academic and specialized 
soft sources – i.e. publications and meetings – but 
academic institutions were among the least popular 
sources. Half of the industry’s innovative firms have 
cooperated to achieve innovation, which is double the 
national average. The proportion of firms considering 
cooperation with academic institutions as fruitful for 
innovation has increased greatly, which contrasts 
with the drop in collaborations with suppliers and 
customers in the private sector. The health industry 
considers high innovation costs, lack of financial re-
sources and market conditions to be important bar-
riers to innovation. 
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ANNEX 1
LIST OF STRATEGMED 
PROJECTS 
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Medtech innovation
1. The method of treating large bone tissue defects in oncological patients with the use of in vivo tissue engineering
2. The personalization of the treatment of acute lymphoblastic leukemia in children in Poland
3. A new model of medical care with the use of the modern methods of non-invasive clinical assessment and telemedicine in patients with cardiac insufficiency
4. New anti-neoplastic compounds disturbing the functions of telomeres
5. 3D bioprinting of scaffolding with the use of live pancreatic islets or insulin-producing cells for the purpose of creating a bionic pancreas
6. Diagnostics of gliomas on the basis of the free-circulating tumor DNA
7. The application of the new methods of diagnosing and treating epilepsy and neurodevelopmental disorders in children on the basis of the clinical and cellular model of mTOR pathway dependent epilepsy
8. Developing optimized methods of treating tissue damage on the basis of innovative composites and mesenchymal stem cells and their derivatives in patients with civilization diseases
9. A virtual clinic of balance
10. A new therapy of psychotic disorders and the Huntington disease with particular emphasis on cognitive deficits
11. Developing new therapies based on the stimulation of antineoplastic action of the immune system
12. An innovative technet (99Mo/99mTc) generator with a chitosan-based microporous sorbent using molybdenum 99Mo, for applications in isotopic diagnostics
13. Developing and assessing comprehensively a biodegradable and flexible intravascular balloon expandable stent based on thin and highly resistant struts
14.
Developing a reference model of Personalized Neoplastic Tumors Diagnostics based on tumor heterogeneity 
analysis with the use of genome biomarkers, transcriptome and metabolome as well as PET/MRI imaging as a 
tool for implementing and monitoring individualized therapies
15. Non-invasive monitoring in the early diagnosing of atrial fibrillation (AF)
16. Developing an innovative technology of producing laser micro-probes to be used in neoplastic diagnostics
17. New tools of molecular diagnostics and imagining in individualized breast, thyroid, and prostatic carcinoma therapies
18. An integrated system for transcatheter closure of paravalvular leaks 
19. Pre-clinical and clinical studies on antineoplastic action of a new TRAIL-derivative molecule oriented towards signaling cell death – establishing a national center for early phase clinical oncological studies 
20. Regeneration of ischemic injuries of the cardio-vascular system with the use of Wharton jelly as an unlimited therapeutic source of stem cells
21. Mesenchymal stromal cells and a scaffold enriched with such cells as an alternative therapy for patients with cardiac insufficiency
22. Therapeutic potential of mesenchymal stem cells tested in clinical trials and in vitro – a justification for banking characterized cells
23. An innovative system for diagnosing and treating disequilibrium
24. A bio-cybernetic system for predicting and monitoring organ complications resulting from hypertension with the use of non-invasive diagnostic methods and wireless cardiovascular system sensors 
25. Developing modern biomarkers and an innovative FGFR kinase inhibitor used in antineoplasmic therapies
26. Introducing an original Polish implantable rotary heart assist pump and a remote monitoring and rehabilitation system for patients with heart assist devices
27. Using modern telemedical technologies in an innovative optimum cardiac rehabilitation program in patients after coronary revascularization
28. Developing an innovative method of treating Epidermolysis Bullosa and chronic wounds of other origin by means of biological dressing made of human material 
29. Using the regenerative potential of mesenchymal stem cells
30. Using medical data teletransmission for improving quality of life in patients with cardiac insufficiency and reducing costs of treatment
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31. Modern urinary prosthesis for patients with urinary bladder carcinoma after contactless and minimally invasive urinary bladder excision 
32. Using glial progenitors in the treatment of amyotrophic lateral sclerosis
33. Epigenetic therapies in oncology
34. Pharmacotherapy of vascular endothelium and platelet activation dependent on prostacyclin, nitrogen oxide and carbon oxide – a new strategy for preventing neoplastic metastases
35. Cell-based therapy on the basis of artificially multiplied regulatory lymphocytes CD4+CD25+CD127-
36. Developing and implementing the first Polish low-profile aortic valve implanted subcutaneously
37. Developing a Polish complementary molecular surgical navigation system for the treatment of neoplasms
38. New technologies of pharmacological stimulation of regeneration
39. An innovative strategy of diagnostics, prevention and adjuvant therapy of selected neurodegenerative diseases in the Polish population
40. Low-molecular epigenetic modulators as cell pluripotentiality activators for the needs of regenerative medicine
41. An integrated system of tools for diagnostics and telerehabilitation of sense organ diseases 
42. Innovative methods of tissue engineering supporting the healing and regeneration of tendons and ligaments
43. Using telemedical technologies in a new model of organizing and conducting comprehensive rehabilitation of patients with cardiac insufficiency TELEREH-HF (multi-center research)
44. Treatment of multiple sclerosis by means of transdermal stimulation based on myelin peptides
 
Source: NCBR (2012), The Strategic Programme of Scientific Research and Development Work: Prevention and Treat-
ment of Civilization Diseases, National Centre for Research and Development, Warsaw, Poland.  https://www.ncbr.gov.
pl/programy/programy-strategiczne/profilaktyka-i-leczenie-chorob-cywilizacyjnych---strategmed/. (https://www.
ncbr.gov.pl/en/programmes/strategic-programmes/news/) 
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